The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial
Open accessAbstract
Background: Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment for locally advanced oesophageal cancer. With this treatment, 29% of patients have a pathologically complete response in the resection specimen. This provides the rationale for investigating an active surveillance approach. The aim of this study is to assess the (cost-)effectiveness of active surveillance vs. standard oesophagectomy after nCRT for oesophageal cancer. Methods: This is a phase-III multi-centre, stepped-wedge cluster randomised controlled trial. A total of 300 patients with clinically complete response (cCR, i.e. no local or disseminated disease proven by histology) after nCRT will be randomised to show non-inferiority of active surveillance to standard oesophagectomy (non-inferiority margin 15%, intra-correlation coefficient 0.02, power 80%, 2-sided α 0.05, 12% drop-out). Patients will undergo a first clinical response evaluation (CRE-I) 4–6 weeks after nCRT, consisting of endoscopy with bite-on-bite biopsies of the primary tumour site and other suspected lesions. Clinically complete responders will undergo a second CRE (CRE-II), 6–8 weeks after CRE-I. CRE-II will include 18F–FDG-PET-CT, followed by endoscopy with bite-on-bite biopsies and ultra-endosonography plus fine needle aspiration of suspected lymph nodes and/or PET- positive lesions. Patients with cCR at CRE-II will be assigned to oesophagectomy (first phase) or active surveillance (second phase of the study). The duration of the first phase is determined randomly over the 12 centres, i.e., stepped-wedge cluster design. Patients in the active surveillance arm will undergo diagnostic evaluations similar to CRE-II at 6/9/12/16/20/24/30/36/48 and 60 months after nCRT. In this arm, oesophagectomy will be offered only to patients in whom locoregional regrowth is highly suspected or proven, without distant dissemination. The main study parameter is overall survival; secondary endpoints include percentage of patients who do not undergo surgery, quality of life, clinical irresectability (cT4b) rate, radical resection rate, postoperative complications, progression-free survival, distant dissemination rate, and cost-effectiveness. We hypothesise that active surveillance leads to non-inferior survival, improved quality of life and a reduction in costs, compared to standard oesophagectomy. Discussion: If active surveillance and surgery as needed after nCRT leads to non-inferior survival compared to standard oesophagectomy, this organ-sparing approach can be implemented as a standard of care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., Swinburn, P., & Busschbach, J. (2013) · Quality of Life Research · doi:10.1007/s11136-012-0322-4 · Cited by 1,582
The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting
Hemming, K., Haines, T. P., Chilton, P. J., Girling, A. J., & Lilford, R. J. (2015) · BMJ · doi:10.1136/bmj.h391 · Cited by 1,410
The stepped wedge trial design: a systematic review
Brown, C. A., & Lilford, R. J. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-54 · Cited by 907
Cited by
Recent progress in multidisciplinary treatment for patients with esophageal cancer
Watanabe, M., Otake, R., Kozuki, R., Toihata, T., Takahashi, K., Okamura, A., & Imamura, Y. (2020) · Surgery Today · doi:10.1007/s00595-019-01878-7 · Cited by 428
Contemporary radiotherapy: present and future
Chandra, R. A., Keane, F. K., Voncken, F. E. M., & Thomas, C. R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00233-6 · Cited by 380
Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline
Shah, M. A., Kennedy, E. B., Catenacci, D. V., Deighton, D. C., Goodman, K. A., Malhotra, N. K., Willett, C., Stiles, B., Sharma, P., Tang, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00866 · Cited by 333
Self-citation
Metadata
- Authors
- on behalf of the SANO-study group, Noordman, B. J., Wijnhoven, B. P. L., Lagarde, S. M., Boonstra, J. J., Coene, P. P. L. O., Dekker, J. W. T., Doukas, M., van der Gaast, A., Heisterkamp, J., Kouwenhoven, E. A., Nieuwenhuijzen, G. A. P., Pierie, J.-P. E. N., Rosman, C., van Sandick, J. W., van der Sangen, M. J. C., Sosef, M. N., Spaander, M. C. W., Valkema, R., van der Zaag, E. S., Steyerberg, E. W., & van Lanschot, J. J. B.
- Venue
- BMC Cancer
- Published
- 2018-02-06
- Volume
- 18
- Issue
- 1
- Pages
- 142-142
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2788485956
- Cited by
- 238
- References
- 5
- FWCI
- 25.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. https://app.cochat.ai/papers/10.1186/s12885-018-4034-1
- The paper
- on behalf of the SANO-study group, Noordman, B. J., Wijnhoven, B. P. L., Lagarde, S. M., Boonstra, J. J., Coene, P. P. L. O., Dekker, J. W. T., Doukas, M., van der Gaast, A., Heisterkamp, J., Kouwenhoven, E. A., Nieuwenhuijzen, G. A. P., Pierie, J.-P. E. N., Rosman, C., van Sandick, J. W., van der Sangen, M. J. C., Sosef, M. N., Spaander, M. C. W., Valkema, R., . . . van Lanschot, J. J. B. (2018). Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer. https://doi.org/10.1186/s12885-018-4034-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.